EGFR and non-small cell lung carcinoma: The current guidelines and drug-approved companion diagnostics favor a limited single gene assay analysis for EGFR mutation in NSCLC patients, limiting our knowledge of how the most common simultaneous somatic mutations may impact the clinical outcome of EGFR-TKI treatment.